Ondansetron with and without naltrexone as a treatment of biologic alcoholism: Concepts and updated findings

Addictive Disorders and their Treatment

Volumn 1, Issue 3, 2002, Pages 75-80

  Ait Daoud, Nassima ^a   Johnson, Bankole A ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Alcoholism; Humans; Naltrexone; Ondansetron; Subtype; Treatment

Indexed keywords

NALTREXONE; ONDANSETRON; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; COMBINATION CHEMOTHERAPY; DRINKING BEHAVIOR; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 1242268203     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132576-200209000-00001     Document Type: Review

References (82)

1. Miller WR, Hester RK. The effectiveness of alcoholism treatment methods: what research reveals. In: Miller WR, Heather N, eds. Treating Addictive Behaviors: Process of Change. New York, NY: Plenum; 1986:121-174.
2. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482-1490.
3. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992;654:171-191.
4. Hemby SE, Johnson BA, Dworkin SI. Neurobiological basis of drug reinforcement. In: Johnson A, Roache D, eds. Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior. Philadelphia: Lippincott-Raven; 1997.
5. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000;149:327-344.
6. Penick EC, Nickel EJ, Powell BJ, et al. The comparative validity of eleven alcoholism typologies. J Stud Alcohol 1999;60:188-202.
7. Irwin M, Schuckit M, Smith TL. Clinical importance of age at onset in type 1 and type 2 primary alcoholics. Arch Gen Psychiatry 1990;47:320-324.
8. von Knorring L, Smigan L, et al. Personality traits in subtypes of alcoholics. J Stud Alcohol 1987;48:523-527.
9. Babor TF, Dolinsky ZS, Meyer RE, et al. Types of alcoholics: concurrent and predictive validity of some common classification schemes. Br J Addict 1992;87:1415-1431.
10. Johnson BA, Cloninger CR, Roache JD, et al. Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population. Am J Addict 2000;9:17-27.
11. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism [published erratum appears in Arch Gen Psychiatry 1996;53:555]. Arch Gen Psychiatry 1996;53:250-257.
12. Fils-Aime ML, Eckardt MJ, George DT, et al. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry 1996;53:211-216.
13. Swann AC, Johnson BA, Cloninger CR, et al. Relationships of plasma tryptophan availability to course of illness and clinical features of alcoholism: a preliminary study. Psychopharmacology 1999;143:380-384.
14. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry 1994;36:326-337.
15. Lovinger DM, White G. Ethanol potentiation of 5-hydroxytryptamine3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol Pharmacol 1991;40:263-270.
16. Zhou Q, Lovinger DM. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. J Pharmacol Exp Ther 1996;278:732-740.
17. Lovinger DM, Zhou Q. Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology 1994;33:1567-1572.
18. Lovinger DM. Inhibition of 5-HT3 receptor-mediated ion current by divalent metal cations in NCB-20 neuroblastoma cells. J Neurophysiol 1991;66:1329-1337.
19. Lovinger DM. Ethanol potentiates ion current mediated by 5-HT3 receptors on neuroblastoma cells and isolated neurons. Alcohol Alcohol Suppl 1991;1:181-185.
20. Lovinger DM. 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic. Neurochem Int 1999;35:125-130.
21. Johnson BA, Cowen PJ. Alcohol-induced reinforcement: dopamine and 5-HT3 receptor interactions in animals and humans. Drug Dev Res 1993;30:153-169.
22. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987:94:469-492.
23. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152.
24. Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987;330:746-748.
25. Oxford AW, Bell JA, Kilpatrick GJ, et al. Ondansetron and related 5-HT3 antagonists: recent advances. Prog Med Chem 1992;29:239-270.
26. Kilpatrick GJ, Hagan RM, Gale JD. 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Behav Brain Res 1996;73:11-13.
27. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-5278.
28. Fadda F, Garau B, Marchei F, et al. MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol Alcohol 1991;26:107-110.
29. Yoshimoto K, McBride WJ, Lumeng L, et al. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 1992;9:17-22.
30. Bloom FE, Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998;23:653-659.
31. Yoshimoto K, Yayama K, Sorimachi Y, et al. Possibility of 5-HT3 receptor involvement in alcohol dependence: a microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption. Alcohol Clin Exp Res 1996;20(9 suppl):311A-319A.
32. Bradbury AJ, Costall B, Domeney AM, et al. Laterality of dopamine function and neuroleptic action in the amygdala in the rat. Neuropharmacology 1985;24:1163-1170.
33. Hagan RM, Jones BJ, Jordan CC, et al. Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. Br J Pharmacol 1990;99:227-232.
34. Eison AS, Iversen SD, Sandberg BE, et al. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. Science 1982;215:188-190.
35. Costall B, Domeney AM, Naylor RJ, et al. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987;92:881-894.
36. Hodge CW, Samson HH, Lewis RS, et al. Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205-930. Alcohol 1993;10:191-196.
37. Rodd-Henricks ZA, McKinzie DL, Li TK, et al. Intracranial self-administration of ethanol into the posterior VTA of Wistar rats is mediated by 5-HT3 receptors. Paper presented at: Scientific meeting of the Research Society on Alcoholism; 1999; Santa Barbara, CA.
38. Johnson BA, Campling GM, Griffiths P, et al. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology 1993;112:142-144.
39. Meert TF. Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 1993;28:157-170.
40. Dyr W, Kostowski W. Evidence that the amygdala is involved in the inhibitory effects of 5-HT receptor antagonists on alcohol drinking in rats. Alcohol 1995;12:387-391.
41. Sellers EM, Higgins GA, Tompkins DM, et al. Serotonin and alcohol drinking. NIDA Res Monogr 1992;119:141-145.
42. McBride WJ, Li TK. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol 1998;12:339-369.
43. Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology 1995;117:479-485.
44. Beardsley PM, Lopez OT, Gullikson G, et al. Serotonin 5-HT3 antagonists fail to affect ethanol self-administration of rats. Alcohol 1994;11:389-395.
45. Johnson V, Pandina RJ. Affectivity, family drinking history, and the development of problem drinking: a longitudinal analysis. J Appl Soc Psychol 1993;23:2055-2073.
46. Swift RM, Davidson D, Whelihan W, et al. Ondansetron alters human alcohol intoxication. Biol Psychiatry 1996;40:514-521.
47. Doty P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 1994;5:461-469.
48. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994;18:879-885.
49. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:5444.
50. Linnoila M, Virkkunen M, George T, et al. Impulse control disorders. Int Clin Psychopharmacol 1993;8(suppl 1):53-56.
51. Linnoila MI. Benzodiazepines and alcohol. J Psychiatr Res 1990;24(suppl 2):121-127.
52. Buydens-Branchey L, Branchey MH, Noumair D. Age of alcoholism onset. I. Relationship to psychopathology. Arch Gen Psychiatry 1989;46:225-230.
53. Linnoila M, Virkkunen M. Biologic correlates of suicidal risk and aggressive behavioral traits. J Clin Psychophannacol 1992;12(2 supp1):19S-20S.
54. Linnoila M, Virkkunen M. Psychopharmacology of depression. In: Montgomery SA, ed. British Association for Psychopharmacology Monograph. Oxford: Oxford University Press; 1994:170-184.
55. Linnoila M, Stapleton JM, George DT, et al. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychophannacol 1993;13:175-180.
56. Linnoila M. Handbook of Antisocial Behavior. New York, NY: John Wiley & Sons; 1997.
57. Johnson BA, Roache JD, Ait-Daoud N, et al. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology. 2002;160:408-413.
58. Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept - an hypothesis. Alcohol Clin Exp Res 2000;24:1597-1601.
59. Barnes JM, Barnes NM, Champaneria S, et al. Characterization and autoradiographic localization of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neurophartnacohgy 1990;29:1037-1045.
60. Perry DC. Autoradiography of [3H]quipazine in rodent brain. Eur J Pharmacol 1990;187:75-85.
61. Yoshimoto K, McBride WJ. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 1992;17:401-407.
62. Campbell AD, McBride WJ. Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens. Pharmacol Biochem Behav 1995;51:835-842.
63. Gianoulakis C. The effect of ethanol on the biosynthesis and regulation of opioid peptides. Experientia 1989;45:428-435.
64. Reid LD, Hunter GA. Morphine and naloxone modulate intake of ethanol. Alcohol 1984;1:33-37.
65. Hubbell CL, Czirr SA, Reid LD. Persistence and specificity of small doses of morphine on intake of alcoholic beverages. Alcohol 1987;4:149-156.
66. Hubbell CL, Czirr SA, Hunter GA, et al. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 1986;3:39-54.
67. Carboni E, Acquas E, Leone P, et al. 5-HT3 receptor antagonists block morphine- and nicotine-induced place-preference conditioning. Eur J Pharmacol 1988;151:159-160.
68. Carboni E, Acquas E, Frau R, et al. Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 1989;164:515-519.
69. Imperato A, Angelucci L. 5-HT3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neurosci Lett 1989;101:214-217.
70. Pei Q, Zetterstrom T, Leslie RA, et al. 5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol 1993;230:63-68.
71. Matsuzawa S, Suzuki T, Misawa M, et al. Roles of 5-HT3 and opioid receptors in the ethanol-induced place preference in rats exposed to conditioned fear stress. Life Sci 1999;64:PL241-PL249.
72. Widdowson PS, Holman RB. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J Neurochem 1992;59:157-163.
73. Le AD, Sellers EM. Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake. Alcohol Alcohol Suppl 1994;2:545-549.
74. Ait-Daoud N, Johnson BA, Prihoda TJ, et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 2001;154:23-27.
75. Ait-Daoud N, Johnson BA, Javors M, et al. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. Alcohol Clin Exp Res 2001;25:847-849.
76. Anton RF, Moak DH. Carbohydrate-deficient transferrin and gamma-glutamyltransferase as markers of heavy alcohol consumption: gender differences. Alcohol Clin Exp Res 1994;18:747-754.
77. Stibler H, Borg S, Joustra M. A modified method for the assay of carbohydrate-deficient transferrin (CDT) in serum. Alcohol Alcohol Suppl 1991;1:451-454.
78. Stibler H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029-2037.
79. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: L. Erlbaum Associates; 1988.
80. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 1997;54:737-742.
81. Gale JD. Serotonergic mediation of vomiting. J Pediatr Gastroenterol Nutr 1995;21(suppl 1):S22-S28.
82. Wilde MI, Markham A, Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773-794.